Ligand Pharmaceuticals Inc. (NASDAQ: LGND) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT LIGAND PHARMACEUTICALS INC.

Ligand Pharmaceuticals Inc. (NASDAQ: LGND)
Listen to this Section


$238.54
+2.6250 ( +1.11% ) 63.4K

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Market Data


Open $238.54
Previous Close $235.91
Volume 63.4K
Market Cap $4.70B
Day Range $233.27 - $240.11
52 Week Range $102.50 - $247.38
Shares Outstanding 20.04M
Change % +1.11%
Net Change ▲ 2.6250
Insider Ownership 0.00%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology
IPO Year1994
CountryUnited States

Insider Ownership Transactions

Total Amount Purchased: -137,281.00

Date Type Amount Purchased Purchaser
2024-06-18 Sale -1252.00 KOZARICH JOHN W
2024-06-18 Sale -1252.00 Haas Jason
2024-06-18 Sale -1252.00 Gray Nancy Ryan
2024-06-18 Sale -1252.00 Aryeh Jason
2024-06-18 Sale -1252.00 Zimmermann Martine
2024-05-17 Sale -934.00 Gray Nancy Ryan
2024-05-17 Sale -5873.00 Espinoza Octavio
2024-05-15 Sale -3440.00 Korenberg Matthew E
2024-05-13 Sale -10000.00 Reardon Andrew
2024-05-02 Sale -2406.00 Aryeh Jason

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Nov 12, 2025
4 Insider transactions 1 Nov 12, 2025
4 Insider transactions 1 Nov 10, 2025
10-q Quarterly Reports 77 Nov 07, 2025
8-k 8K-related 14 Nov 06, 2025
4 Insider transactions 1 Nov 05, 2025
4 Insider transactions 1 Oct 03, 2025
4 Insider transactions 1 Sep 24, 2025
4 Insider transactions 1 Sep 24, 2025
8-k 8K-related 13 Sep 16, 2025

Latest News


× Before browsing our site, please accept our cookies policy